2030 Competition Healthcare Provider 
World of DTC Marketing
AUGUST 19, 2022
Congress has taken decisive action to reduce drug prices while ignoring that overall healthcare spending will be a substantial part of GNP. 1ne: A new analysis predicts that by 2030, 48.9% Without this competition, these near-monopolies have providers and insurers in a position where they can drive up their prices unopposed.
Contrarian Sales Techniques
JANUARY 30, 2023
According to the Bureau of Labor Statistics, employment of medical and pharmaceutical sales representatives is projected to grow 3 percent from 2020 to 2030, about as fast as the average for all occupations. However, the industry is becoming more competitive and navigating the industry is becoming harder.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
pharmaphorum
JANUARY 24, 2023
In this final instalment of IQVIA EMEA Thought Leadership’s Nine for 2023 three-part series, focusing on issues that will change the direction of healthcare and the pharmaceutical industry this year, three key competitive issues for pharmaceutical companies in 2023 are assessed.
LEVO Health
MAY 8, 2024
Fragmented Care: A lack of coordination across healthcare providers can make navigating the system challenging for patients. Time Constraints and Accessibility: Busy schedules and limited healthcare access hinder patient engagement. Portals can also facilitate secure messaging with healthcare providers.
Every Ancillary
MAY 14, 2021
According to one estimate from P&S Research , this market is expected to grow nearly 5x by 2030! Cons: Highly competitive with new options continually emerging. The Regenerative Medicine sector has exploded in popularity in recent years, with that trend expected to continue for the foreseeable future. Opportunities: Liquid Amnion.
European Pharmaceutical Review
DECEMBER 21, 2022
16,17 However, care must be taken to ensure that chemicals from biomass are not produced in competition with food production and do not have a negative impact on the environment or natural habitats. The lengthy validation of defossilised organic chemicals and plastics for the healthcare sector will take several years.
PM360
AUGUST 9, 2022
With these launches came more complex science, which pushed biopharma’s evolution to integrate more medical engagement alongside the existing commercial focus for healthcare providers and payers. Ask: Is this component truly a competitive advantage? Challenges of the New World Order. Am I making the customer’s life easier?
Expert insights. Personalized for you.
204 
Let's personalize your content